Tyra Biosciences (TYRA) Assets Average (2021 - 2026)
Tyra Biosciences' (TYRA) quarterly Assets Average came in at $347.3 million in Q1 2026, down 1.75% YoY from $353.5 million in Q1 2025, and up 18.85% on a QoQ basis from $292.2 million in Q4 2025.
Tyra Biosciences (TYRA) Assets Average (2021 - 2026) Analysis & Trends
Tyra Biosciences (TYRA) has 6 years of Assets Average data on file, last reported at $347.3 million in Q1 2026.
- Quarterly Assets Average fell 1.75% year-over-year to $347.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $347.3 million (down 1.75% YoY) and the FY2025 annual result came in at $323.1 million, up 9.63% from the prior year.
- Assets Average climbed to $347.3 million in Q1 2026, from $292.2 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $398.6 million in Q2 2024 to a low of $232.1 million in Q4 2023.
- A 5-year average of $308.7 million and a median of $302.8 million in 2022 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2024 — Assets Average surged 60.3% — and 2025, when it slipped 21.46%.
- Tracing TYRA's Assets Average over 5 years: stood at $271.1 million in 2022, then declined by 14.38% to $232.1 million in 2023, then surged by 60.3% to $372.1 million in 2024, then retreated by 21.46% to $292.2 million in 2025, then rose by 18.85% to $347.3 million in 2026.
- The last three Assets Average figures came in at $347.3 million (Q1 2026), $292.2 million (Q4 2025), and $311.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Tyra Biosciences | 1.51 Bn | 1.51 Bn | - | 397.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 397.70 Mn |
| Mar 31, 2026 | 347.32 Mn |
| Dec 31, 2025 | 292.23 Mn |
| Sep 30, 2025 | 311.68 Mn |
| Jun 30, 2025 | 332.49 Mn |
| Mar 31, 2025 | 353.52 Mn |
| Dec 31, 2024 | 372.08 Mn |
| Sep 30, 2024 | 386.53 Mn |
| Jun 30, 2024 | 398.60 Mn |
| Mar 31, 2024 | 315.30 Mn |
| Dec 31, 2023 | 232.11 Mn |
| Sep 30, 2023 | 244.19 Mn |
| Jun 30, 2023 | 252.53 Mn |
| Mar 31, 2023 | 260.62 Mn |
| Dec 31, 2022 | 271.08 Mn |
| Sep 30, 2022 | 281.55 Mn |
| Jun 30, 2022 | 293.04 Mn |
| Mar 31, 2022 | 302.84 Mn |
| Dec 31, 2021 | 311.34 Mn |